Physician profile
Devendra S Kahlon
NPI 1285668897
$2,753.33
in general payments reported to CMS, 2019-2025
20 companies · $452 in 2025
The $452 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $193 · 2021: $389 · 2022: $288 · 2023: $634 · 2024: $649 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,734.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,068.19 | 2019-2025 | |
| Gilead Sciences, INC. | $299.34 | 2019-2025 | |
| Janssen Biotech, INC. | $260.81 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $216.25 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $170.91 | 2023-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.97 | 2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $76.64 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $73.40 | 2019-2023 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.04 | 2022-2025 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $65.90 | 2019-2022 | |
| Celgene Corporation | $62.62 | 2022 | |
| Evoke Pharma, INC. | $61.16 | 2020-2021 | |
| Braintree Laboratories, INC. | $57.76 | 2022-2023 | Sutab |
| Vivus LLC | $45.18 | 2021 | |
| Enterra Medical, INC. | $32.22 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $25.50 | 2024 | Terlivaz |
| Genzyme Corporation | $21.99 | 2024 | |
| Ucb, INC. | $19.10 | 2020 | |
| Biogen, INC. | $18.50 | 2021 | |
| Ardelyx, INC. | $14.85 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devendra Kahlon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.